Correct re funding until end of healthy human trial and to completion of radio labelled tracer - noting GE collaboration is funded by milestone payments from GE.
Then in relation to the second leg of trial, you are also correct that the introduction of this step and the tracer adds significant value to the phase 1 as along with safety data the company can may be able to demonstrate that AD-214 get to the lungs of patients and that it acts directly on fibrosis. This bring forward partnering discussions and improve potential terms (upfront payments, milestones and royalties) as it would be a strong proxy for efficacy in humans and perhaps provide confidence to apply the approach to other relevant indications. I see the amendment making the second part of the phase 1 as a proxy to a phase 2a potentially, potentially shortening phase 2 timeframes and costs also.
Exciting 8 months coming up for the company.
1AD Price at posting:
7.9¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)